摘要
目的了解医院治疗多药耐药鲍氏不动杆菌相关肺部感染的抗菌药物使用情况,对抗菌药物治疗效果进行评估分析。方法对2013年1月-2015年12月医院内治疗肺部感染的多药耐药鲍氏不动杆菌的抗菌药物使用情况及患者临床结局进行统计分析。结果调查年份治疗多药耐药鲍氏不动杆菌的抗菌药物中碳青霉烯类使用率最高,亚胺培南占47.32%,其次是加β-内酰胺酶抑制剂青霉素类及头孢菌素类,分别为20.24%和16.37%;联合用药效果略优于单药治疗方案;多药耐药鲍氏不动杆菌感染病例粗死亡率略高于非多药耐药鲍氏不动杆菌病例粗死亡率。结论多药耐药鲍氏不动杆菌呼吸道感染患者粗死亡率较高,临床应引起高度重视,控制多药耐药鲍氏不动杆菌感染发生。
OBJECTIVE To investigate the status of use of antibiotics for treatment of pulmonary infections caused by multidrug-resistant Acinetobacter baumannii（MDRAB）so as to evaluate the curative effects of antibiotics.METHODS The patients with MDRAB pulmonary infections who were treated in hospitals from Jan 2013 to Dec2015 were enrolled in the study,and the utilization rates of antibiotics and clinical outcomes were statistically analyzed.RESULTS Among the antibiotics that were used for treatment of the MDRAB infections,the utilization rate of carbapenems was the highest,imipenem accounted for 47.32%,and the antibiotics containingβ-lactamase inhibitors penicillins and cephalosporins accounted for 20.24% and 16.37%,respectively.The curative effect of the combined drug therapy was better than that of the one-drug therapy.The crude mortality rate of the patients with MDRAB infections was slightly higher than that of the patients with non-MDRAB infections.CONCLUSION The crude mortality rate of the patients with MDRAB respiratory tract infection is high,which should be attached great importance by the hospital so as to control the MDRAB infections.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2018年第5期675-678,共4页
Chinese Journal of Nosocomiology
关键词
多药耐药
鲍氏不动杆菌
肺部感染
抗菌药物
Multidrug-resistant
Acinetobacter baumannii
Pulmonary infection
Antibiotic
